“Plaintiffs Actelion Pharmaceuticals US, Inc. and Actelion Pharmaceuticals Ltd (together, “Actelion”) and Nippon Shinyaku Co., Ltd. (“Nippon Shinyaku”) (collectively, “Plaintiffs”) and Defendants VGYAAN Pharmaceuticals LLC (“VGYAAN”) and RK Pharma, Inc. (collectively, “Defendants”) (all parties collectively, the “Parties”), by their respective undersigned attorneys, hereby stipulate and consent to entry of judgment and injunction in this action as follows: IT IS, this 3rd day of December, 2025, HEREBY ORDERED, ADJUDGED AND DECREED that: 1. For purposes of this action only, this Court has jurisdiction over the subject matter of the above action and has personal jurisdiction over the Parties. 2. As used in this Consent Judgment and Order of Permanent Injunction, (i) the term “the ’302 Patent” means U.S. Patent No. 7,205,302, which Defendants agree is valid and enforceable, (ii) the term “Defendants’ ANDA Products” means the products described in Abbreviated New Drug Application (“ANDA”) No. 214055 (“Defendants’ ANDA”), namely selexipag tablets (200 mcg, 400 mcg, 600 mcg, 800 mcg, 1000 mg, 1200 mcg, 1400 mcg, and 1600 mcg) as a generic version of Uptravi® tablets as existing on the date of entry of this Consent Judgment, and as amended or supplemented from time to time in the ordinary course of business, (iii) the term “Affiliate” shall mean any entity controlling, controlled by, or under common control with a Party, but only as long as such control continues, where “control” means: (1) the ownership of at least fifty percent (50%) of the equity or beneficial interest of such entity, or the right to vote for or appoint a majority of the board of directors or other governing body of such entity; or (2) the power to directly, or indirectly direct or cause the direction of the management and policies of such entity by any means whatsoever. 3. Unless otherwise authorized by Plaintiffs, Defendants, including any of their successors and assigns, are enjoined from making, using, selling or offering to sell in, or importing into, the United States Defendants’ ANDA Products, on their own part or through any Affiliate, officer, agent, servant, employee or attorney, or through any person in concert or coordination with Defendants or their Affiliates, until and after the expiration of the ’302 Patent, including any patent term extensions and/or patent term adjustments and during the period of any associated exclusivity, including pediatric exclusivity. 4. The Parties agree that jurisdiction and venue for an action to enforce performance under this Consent Judgment and Order of Permanent Injunction, including for a preliminary injunction against the breaching conduct, exists in this District Court, and the Parties hereby waive any and all defenses based on personal jurisdiction and venue. 5. The Parties waive all right to appeal or otherwise move for relief from this Judgment and Order.”